Hydroxyzine Use in Infants
Hydroxyzine is approved for use in infants and children under 6 years of age at a dose of 50 mg daily in divided doses for both anxiety/tension and pruritus, according to FDA labeling. 1
FDA-Approved Dosing
The FDA drug label provides clear dosing guidance for the pediatric population 1:
- Children under 6 years: 50 mg daily in divided doses
- Children over 6 years: 50-100 mg daily in divided doses
- As premedication/sedation: 0.6 mg/kg of body weight in children
These doses apply to both anxiety/tension management and pruritus from allergic conditions (chronic urticaria, atopic dermatitis, contact dermatoses).
Evidence-Based Dosing from Clinical Studies
Research supports a more weight-based approach. A pharmacokinetic study in children with atopic dermatitis (mean age 6.1 years) demonstrated that 0.7 mg/kg three times daily was as effective as 1.4 mg/kg three times daily for pruritus relief, with significantly less sedation at the lower dose 2. This study showed greater than 85% pruritus suppression from 2-12 hours post-dose, with an elimination half-life of 7.1 hours that increases with age.
Multiple pediatric sedation studies used 3.7 mg/kg as a single oral dose in young children (mean age 29-61 months) for dental procedures, demonstrating successful sedation when combined with nitrous oxide 3, 4.
Critical Safety Considerations
Contraindications
Hydroxyzine is contraindicated in early pregnancy due to fetal abnormalities in animal studies 1. It is also contraindicated in patients with prolonged QT interval, which is particularly relevant given cardiac safety concerns 1.
Important Safety Signals
A 2021 population-based study raises significant neurodevelopmental concerns 5. Children under 5 years with repeat prescriptions (versus single prescription) showed increased odds ratios for:
- Tic disorders: 1.55 (95% CI: 1.23-1.96)
- Anxiety: 1.34 (95% CI: 1.05-1.70)
- Conduct disturbances: 1.34 (95% CI: 1.08-1.66)
This study suggests using the shortest possible duration in preschool-age children until controlled studies confirm long-term safety.
Toxicity Profile
A documented case of hydroxyzine toxicity in a 13-month-old infant (plasma level 102.7 μg/mL) manifested primarily as generalized seizures and sinus tachycardia, requiring physostigmine for seizure control 6. This underscores the need for careful dosing and monitoring.
Practical Dosing Algorithm
For infants and children under 6 years:
- Start with 50 mg daily divided into 2-4 doses (per FDA label) 1
- Alternative weight-based approach: 0.7 mg/kg three times daily for pruritus (based on efficacy data) 2
- For sedation: 0.6 mg/kg as single dose 1 or 3.7 mg/kg for procedural sedation 3, 4
- Limit duration to shortest effective period, especially in children under 5 years, given neurodevelopmental concerns 5
Common Pitfalls to Avoid
- Do not use in infants with cardiac risk factors or prolonged QT interval 1
- Avoid chronic/repeat prescriptions in preschool children when possible due to neurodevelopmental associations 5
- Monitor for excessive sedation, the most common adverse effect 2
- Be aware that elimination half-life increases with age (mean 7.1 hours), affecting dosing frequency 2
- Do not exceed maximum doses to avoid toxicity manifesting as seizures and cardiac effects 6
The evidence supports hydroxyzine use in infants when clinically indicated, but prescribers should use the lowest effective dose for the shortest duration, particularly in children under 5 years.